“This quarter represents a significant step forward for Achieve. After years of focused dedication, we’ve reached the major milestone of submitting our NDA for cytisinicline, established an innovative commercialization partnership with Omnicom, and secured financing to advance our vision,” said Rick Stewart, Chief Executive Officer of Achieve Life Sciences (ACHV). “By combining our evidenced-based science with an agile, technology-driven commercialization strategy, cytisinicline, if approved, would be the first new pharmacotherapy option for nicotine dependence in nearly two decades.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACHV:
- ACHV Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Raymond James Predicts Up to ~760% Surge for These 2 ‘Strong Buy’ Stocks
- Achieve Life Sciences Completes Key Study on Cytisinicline for Renal Impairment
- Achieve Life Sciences management to meet with Cantor Fitzgerald
- Achieve Life Sciences Announces $41.3M Stock Offering